1608 related articles for article (PubMed ID: 17352762)
21. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.
Lima VD; Hogg RS; Harrigan PR; Moore D; Yip B; Wood E; Montaner JS
AIDS; 2007 Mar; 21(6):685-92. PubMed ID: 17413689
[TBL] [Abstract][Full Text] [Related]
22. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Jaspan HB; Berrisford AE; Boulle AM
Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
[TBL] [Abstract][Full Text] [Related]
23. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
Etard JF; Ndiaye I; Thierry-Mieg M; Guèye NF; Guèye PM; Lanièce I; Dieng AB; Diouf A; Laurent C; Mboup S; Sow PS; Delaporte E
AIDS; 2006 May; 20(8):1181-9. PubMed ID: 16691070
[TBL] [Abstract][Full Text] [Related]
24. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study.
Anderson KB; Guest JL; Rimland D
Clin Infect Dis; 2004 Nov; 39(10):1507-13. PubMed ID: 15546088
[TBL] [Abstract][Full Text] [Related]
26. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
[TBL] [Abstract][Full Text] [Related]
27. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
[TBL] [Abstract][Full Text] [Related]
28. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
29. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
[TBL] [Abstract][Full Text] [Related]
30. Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study.
Nicolatou-Galitis O; Velegraki A; Paikos S; Economopoulou P; Stefaniotis T; Papanikolaou IS; Kordossis T
Oral Dis; 2004 May; 10(3):145-50. PubMed ID: 15089923
[TBL] [Abstract][Full Text] [Related]
31. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
[TBL] [Abstract][Full Text] [Related]
32. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
[TBL] [Abstract][Full Text] [Related]
33. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.
Mussini C; Manzardo C; Johnson M; Monforte Ad; Uberti-Foppa C; Antinori A; Gill MJ; Sighinolfi L; Borghi V; Lazzarin A; Miró JM; Sabin C;
AIDS; 2008 Nov; 22(18):2461-9. PubMed ID: 19005269
[TBL] [Abstract][Full Text] [Related]
34. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
Resino S; Larrú B; Maria Bellón J; Resino R; de José MI; Navarro M; Léon JA; Ramos JT; Mellado MJ; Muñoz-Fernández MA
BMC Infect Dis; 2006 Jul; 6():107. PubMed ID: 16834769
[TBL] [Abstract][Full Text] [Related]
35. Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and HIV-HCV infection.
Cooper CL; Mills E
Int J STD AIDS; 2007 Aug; 18(8):546-50. PubMed ID: 17686217
[TBL] [Abstract][Full Text] [Related]
36. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
Kwong GP; Ghani AC; Rode RA; Bartley LM; Cowling BJ; da Silva B; Donnelly CA; van Sighem AI; Cameron DW; Danner SA; de Wolf F; Anderson RM
AIDS; 2006 Oct; 20(15):1941-50. PubMed ID: 16988515
[TBL] [Abstract][Full Text] [Related]
38. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
Ortega KL; Vale DA; Magalhães MH
J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
[TBL] [Abstract][Full Text] [Related]
39. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
[TBL] [Abstract][Full Text] [Related]
40. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
Ho C; Lee S; Wong Kh; Cheng L; Lam M
HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
